+
Lupin and Zentiva Sign Pact to Commercialise Certolizumab
ECONOMY & POLICY

Lupin and Zentiva Sign Pact to Commercialise Certolizumab

Global Pharma major Lupin (Lupin) and Zentiva Group (Zentiva), a pan-European pharmaceutical company, have entered into a license and supply agreement for commercialisation of Lupin’s biosimilar Certolizumab Pegol, across multiple markets globally.

This strategic alliance aims to accelerate the availability of high-quality, cost-effective biosimilar Certolizumab Pegol to patients worldwide.

Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories. Zentiva will oversee commercialization activities outside USA and Canada, predominantly in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. Lupin will undertake commercialization in the remaining regions, including USA and Canada.

Both parties will invest in the development of the new biosimilar. Lupin will receive an initial payment of $10 million upon execution of the agreement and total development and regulatory milestone payments up to $50 million. The profits from the defined markets will be shared between the two companies.

Certolizumab Pegol is a recombinant, humanized antibody Fab' fragment, with specificity for human tumor necrosis factor alpha (TNFα), conjugated to an approximately 40kDa polyethylene glycol. It is indicated for the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, moderate-to-severe plaque psoriasis and Crohn’s disease.

“Our global development and commercialization partnership with Zentiva, with its pan- European focus, enables Lupin to commercialize this unique biosimilar in its core markets and through Zentiva in Europe,” said Fabrice Egros, President of Corporate Development, Lupin. “This partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions and ensuring accessibility and affordability of transformative therapies worldwide."

Global Pharma major Lupin (Lupin) and Zentiva Group (Zentiva), a pan-European pharmaceutical company, have entered into a license and supply agreement for commercialisation of Lupin’s biosimilar Certolizumab Pegol, across multiple markets globally.This strategic alliance aims to accelerate the availability of high-quality, cost-effective biosimilar Certolizumab Pegol to patients worldwide.Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories. Zentiva will oversee commercialization activities outside USA and Canada, predominantly in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. Lupin will undertake commercialization in the remaining regions, including USA and Canada.Both parties will invest in the development of the new biosimilar. Lupin will receive an initial payment of $10 million upon execution of the agreement and total development and regulatory milestone payments up to $50 million. The profits from the defined markets will be shared between the two companies.Certolizumab Pegol is a recombinant, humanized antibody Fab' fragment, with specificity for human tumor necrosis factor alpha (TNFα), conjugated to an approximately 40kDa polyethylene glycol. It is indicated for the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, moderate-to-severe plaque psoriasis and Crohn’s disease.“Our global development and commercialization partnership with Zentiva, with its pan- European focus, enables Lupin to commercialize this unique biosimilar in its core markets and through Zentiva in Europe,” said Fabrice Egros, President of Corporate Development, Lupin. “This partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions and ensuring accessibility and affordability of transformative therapies worldwide.

Next Story
Real Estate

Omaxe to Develop 450-Acre Township in Indore’s Super Corridor

Omaxe has announced a major expansion in Madhya Pradesh with the acquisition of 450 acres along Indore’s Super Corridor for a modern integrated township. The company will invest Rs 12 billion in the multi-phase project, which is expected to generate Rs 25 billion in revenue over three years.  The development will include residential clusters, commercial and retail zones, schools, healthcare facilities, parks, and green mobility infrastructure. The township aims to support the region’s urban growth and rising infrastructure demand, especially with metro connectivity and major road..

Next Story
Infrastructure Energy

India’s First CBG Plant with Steel Pipeline Integration Launched

CEID Consultants and Engineering has successfully commissioned India’s first Compressed Biogas (CBG) plant integrated via a steel pipeline into a City Gas Distribution (CGD) network. Located in Batala, Gurdaspur (Punjab), the MEPL Bio-energy facility now directly supplies CBG into Gujarat Gas’ grid, eliminating the need for cylinder-based cascade transport and significantly lowering logistics costs. This breakthrough comes after CEID’s earlier deployment of MDPE pipeline offtake at the same plant. The steel pipeline marks a new industry benchmark, enabling continuous, real-time and ..

Next Story
Real Estate

Mittal Builders Plans Landmark Township to Transform Naigaon

Mittal Builders has unveiled a bold urban vision to transform Naigaon into a landmark micro-market in western Mumbai, with plans to unlock 6.5 million sq. ft. of development potential across a 70-acre land parcel. The long-term multi-phase plan has an estimated gross development value (GDV) of over Rs 80 billion. As part of this initiative, Mittal Builders has signed a joint development agreement with The House of Abhinandan Lodha (HoABL) to co-develop a 3 million sq. ft. integrated township, comprising over 4,600 apartments and high-street retail. With a planned investment of Rs 20 billi..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?